Social Determinants of Health in Adult Patients With Schizophrenia Who Received Treatment With TV 46000: Real-World Evidence From a United States Claims Database Analysis
Background
TV-46000, a long-acting injectable risperidone formulation administered subcutaneously once monthly (q1m) or once every 2 months (q2m), is approved for the treatment of schizophrenia in adults. Social determinants of health (SDOH) are nonmedical factors that impact health outcomes, and many individuals with mental illness have unmet social needs. We analyzed United States (US) claims data to examine SDOH in adults with schizophrenia who received TV-46000.
Methods
EVERSANA administrative claims data from July 2018 through February 2024 were examined. Patients were included if they were prescribed TV-46000 and had either ≥2 months of data prior to index date or activity before May 1, 2023. Social demographics were assessed across 10 SDOH categories in patients with available data.
Results
Overall, 715 adult patients with schizophrenia (mean age 44 years; 61% male; 63% with comorbid schizophrenia spectrum/other psychotic disorders) had been prescribed TV-46000 (563 q1m; 152 q2m); 41% (293/715) had Medicaid, 8% (60/715) had Medicare, and 40% (287/715) had dual coverage. 189/715 patients (150 q1m; 39 q2m) had SDOH data available. Most (88%; 167/189) lived in poverty, had limited healthcare access (70%; 133/189), and had experienced food/nutrition insecurity (69%; 130/189). Housing instability affected 44% (83/189) of patients; this was higher among q2m (49%; 19/39) than q1m patients (43%; 64/150). Half (52%; 98/189) had low educational attainment.
Conclusion
A high proportion of patients with schizophrenia who received TV-46000 had unmet social needs. This finding indicates that TV-46000 is being prescribed in a real-world population in whom unmet social needs are common.
